Results 221 to 230 of about 901,705 (329)

RETRACTED: Yuan et al. Green Remanufacturer's Mixed Collection Channel Strategy Considering Enterprise's Environmental Responsibility and the Fairness Concern in Reverse Green Supply Chain. <i>Int. J. Environ. Res. Public Health</i><b>2021</b>, <i>18</i>, 3405. [PDF]

Int J Environ Res Public Health
Yuan X, Tang F, Zhang D, Zhang X.
europepmc   +1 more source

Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults

Clinical Pharmacology in Drug Development, EarlyView.
Abstract AZD7442, a combination of extended half‐life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS‐CoV‐2 variants. This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD7442 in healthy Chinese adults. In this randomized, placebo‐controlled, Phase 1 study, AZD7442
Nanyang Li, Jing Zhang, Wenhong Zhang, Zhongyuan Xu, Xiangcao Yao, Anqi He, Shuyuan Liu, Xiaoyun Ge, Jinxi Liu, Yunfei Li, Cecil Chi‐Keung Chen, Huixia Zhang   +11 more
wiley   +1 more source

Writing for JOOT: raising standards in clinical research and evidence synthesis. [PDF]

J Orthop Traumatol
Migliorini F, Randelli F, Di Martino A, Rivera F.   +3 more
europepmc   +1 more source

Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Safety, pharmacokinetics, and impact of race of pharmacokinetics on monoclonal antibodies tixagevimab and cilgavimab (AZD7442) were assessed in Chinese adult participants in a Phase 2, randomized, double‐blind, placebo‐controlled trial. In total, 272 participants were randomized 3:1 to a single intravenous dose of 600 mg AZD7442 or placebo and
Jing Zhang, Huixia Zhang, Yajuan Zhang, Shuyuan Liu, Xiaoyun Ge, Haiyue Zhang, Yunfei Li, Cecil Chi‐Keung Chen, Oleg Stepanov, Weifeng Tang, Wenhong Zhang   +10 more
wiley   +1 more source

<i>BMJ Connections Mental Health</i>, a new <i>BMJ</i> journal. [PDF]

BMJ Ment Health
Cipriani A.
europepmc   +1 more source

International Editorial Board

, 1977

openalex   +1 more source

A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bepirovirsen, an antisense oligonucleotide in development for the treatment of chronic hepatitis B virus (HBV) infection, is administered from glass vials as a subcutaneous (SC) injection by healthcare professionals (HCPs). A ready‐to‐use prefilled syringe (PFS) assembled with a safety syringe device (SSD) has been developed to make ...
Amir S. Youssef, Poonam Shah, Maxwell Hu, Helene Plein, Abhishek Roy, Ravi Sharma, Sarah Mole, Magdalena Blazejczyk, Wendy Cross, Brian Spears, Samuel Pak, Rejbinder Kaur, Robert Elston, Dickens Theodore, Marjan Hezareh, Ahmed Nader   +15 more
wiley   +1 more source

Correction to "Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma". [PDF]

Biomed Res Int
europepmc   +1 more source

<i>BJPsych Open</i>: celebrating 10 years of publishing excellence: a decade in review. [PDF]

BJPsych Open
Kaufman KR.
europepmc   +1 more source

Selecting a Journal for Publication: Criteria to Consider [PDF]

, 2019
Sarli, Cathy C, Suiter, Amy M
core   +1 more source